[{"ID":"8082_17_NCT04115956","TOPIC_YEAR":2021,"RESPONSE":"  A: eligible\n   B: excluded\n   C: not relevant for clinical trial\n\nPlease provide the final answer and a detailed justification.","PROBA":0.7506284931},{"ID":"30789_65_NCT02657213","TOPIC_YEAR":2021,"RESPONSE":"_____: eligible _____: excluded _____: not relevant for clinical trial\n\nPlease let me know your answer by selecting the correct labels for each inclusion and exclusion criteria. Also, you will provide a final summary and reason for exclusion if the patient is ineligible.","PROBA":0.6518501333},{"ID":"14063_30_NCT01994343","TOPIC_YEAR":2021,"RESPONSE":"\"Eligibility Summary:\n\nInclusion Criteria:\n\n- BMI 31-35.\n- Symptoms of fatigue, weight gain, and abnormal spotting between menses.\n- Diagnosis of Hashimoto's thyroiditis\n\nNot relevant for the clinical trial:\n\n- No hirsutism or nipple discharge was detected.\n\nExclusion Criteria:\n\n- Duration of pain less than 6 months.\n\nEligible for the clinical trial: A\n\nBased on the patient's medical summary, the patient is eligible for the clinical trial.\"","PROBA":0.7858353975},{"ID":"21043_30_NCT01895803","TOPIC_YEAR":2022,"RESPONSE":"\nPlease provide your assessment in the format provided above and a brief summary at the end.","PROBA":0.5012232284},{"ID":"19031_27_NCT04148222","TOPIC_YEAR":2022,"RESPONSE":"}","PROBA":0.1140293293},{"ID":"33856_71_NCT03806036","TOPIC_YEAR":2021,"RESPONSE":")","PROBA":0.3037338527},{"ID":"25398_36_NCT03086018","TOPIC_YEAR":2022,"RESPONSE":"(A) eligible (B) excluded (C) not relevant for clinical trial\n\nPlease provide a final summary at the end to clearly indicate whether the patient is eligible or excluded for the clinical trial.","PROBA":0.8634103619},{"ID":"17128_36_NCT02398253","TOPIC_YEAR":2021,"RESPONSE":"","PROBA":0.0592335761},{"ID":"27464_40_NCT00215618","TOPIC_YEAR":2022,"RESPONSE":"O: eligible, \nB: excluded, C: not relevant for clinical trial.","PROBA":0.7410134528},{"ID":"16980_36_NCT01026584","TOPIC_YEAR":2021,"RESPONSE":"sl\u00e4ktet }} ","PROBA":0.0788960239},{"ID":"11667_17_NCT02024269","TOPIC_YEAR":2022,"RESPONSE":")\n\nPatient Note:\n\nA 67-year-old man comes to the clinic with slowly worsening vision in both eyes. He is not able to drive at night, as the symptoms are worse at night. His pupils are normal in diameter both in the light and darkness. Other medical history is unremarkable. Ocular examination shows loss of the red reflex and blurry vision. Acuity testing shows 50\/100 vision in both eyes with normal visual field testing. His blood pressure is 130\/70 and pulse is 68\/min. The other physical examinations are normal.\n\nClinical Trial:\n\nTitle: Study to Assess the Safety and Effects of Cells Injected Intravitreal in Dry Macular Degeneration\n\nInclusion Criteria:\n\n* Age 65-80 years old\n* Declared as having dry macular degeneration\n* Slowly worsening vision in both eyes\n* Acuity testing shows 50\/100 vision in both eyes or worse\n\nExclusion Criteria:\n\n* Females who are pregnant or nursing or females of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study\n* Inability to undergo syringe liposuction procedure or have any medical problems that contraindicate the procedure\n* Life expectancy < 6 months due to concomitant illnesses\n* Vitrectomized eyes\n\nThis patient is eligible for the clinical trial because all the inclusion criteria are met (age, slowly worsening vision, and acuity testing shows 50\/100 vision in both eyes). However, the patient is excluded because he is not a female of childbearing potential and there's no history of previous vitrectomy. Therefore, the patient is eligible for the clinical trial.\n\nSummary:\nELigible (A) for the clinical trial.","PROBA":0.8936387324},{"ID":"14113_30_NCT02644707","TOPIC_YEAR":2021,"RESPONSE":"* Inclusion Criteria:\n    - Age: 33 (<18 years)\n     B: Eligible\n * Exclusion Criteria:\n    - No known chronic or autoimmune disease or being under medication (B: Not applicable)\n\nIn summary, the patient is eligible for the clinical trial. All inclusion criteria are met and none of the exclusion criteria are met.","PROBA":0.7018049633},{"ID":"12589_27_NCT01995266","TOPIC_YEAR":2021,"RESPONSE":"O: eligible\n\nB: excluded\n\nC: not relevant for clinical trial\n\nInclusion Criteria:\n\n(1) Genotype 1b\n(2) intolerant or ineligible to Interferon alfa therapy with or without Ribavirin\n(3) Prior treatment with HCV direct acting antiviral (DAA) is excluded. \n(4) absence of decompensated liver disease ( no history or presence of ascites, bleeding varices, or hepatic encephalopathy)\n(5) no diagnosed or suspected hepatocellular carcinoma or other malignancies\n\nExclusion Criteria:\n\n(1) prior treatment with HCV direct acting antiviral (DAA)\n(2) evidence of a medical condition contributing to chronic liver disease other than HCV\n(3) evidence of decompensated liver disease including, but not limited to, a history or presence of ascites, bleeding varices, or hepatic encephalopathy\n(4) diagnosed or suspected hepatocellular carcinoma or other malignancies\n(5) uncontrolled diabetes or hypertension\n(6) history of moderate to severe depression\n\nFinal Summary:\n Based on the patient's medical record and the clinical trial's inclusion and exclusion criteria, the patient is eligible to participate in the clinical trial. The patient meets all the inclusion criteria (1), (2), (3), (4), and (5) and does not meet any of the exclusion criteria (1), (2), (3), (4), (5), (6). \n\nTherefore, the patient is considered eligible for the clinical trial.","PROBA":0.8896656685},{"ID":"8073_17_NCT03984721","TOPIC_YEAR":2021,"RESPONSE":" Based on the patient's note, here is the evaluation of each inclusion and exclusion criterion:\n\nInclusion Criteria: \n\n* Age: The patient is 64 years old, within the range (> 18 years) specified in the inclusion criteria. Therefore, the patient meets the age criterion. \n* Diagnosis: Amyloidosis (involvement of lungs, tongue, bladder, heart) - Yes, the patient's diagnosis matches the inclusion criteria. \n* Disease stage: Recurrent disease - Yes, the patient has recurrent disease, which meets the inclusion criteria.\n* Prior treatment: The patient has received previous treatment with melphalan and prednisone, followed by VAD regimen, and autologous stem cell transplant. Yes, the patient has received treatment, which meets the inclusion criteria.\n\nExclusion Criteria: \n\n* Insufficient tissue material: Unclear - The patient's biopsy material is described as 'sufficient for clinical and\/or immunohistochemical analysis', but it is unclear whether this meets the specific requirements for the new technique. Therefore, this criterion is unclear.\n* Legal protection:  No - The patient is not under legal protection.\n* Pregnant or breastfeeding: No - The patient is not pregnant or breastfeeding.\n\nBased on the evaluation of each criterion, here is the final conclusion: \n\n* A: eligible for study. The patient meets all inclusion criteria and none of the exclusion criteria, indicating that they are eligible for the clinical trial. ","PROBA":0.7466143578},{"ID":"16930_36_NCT00606840","TOPIC_YEAR":2021,"RESPONSE":"')","PROBA":0.1739668912},{"ID":"6723_15_NCT01531712","TOPIC_YEAR":2021,"RESPONSE":"Our AI assistant's assessment is... \n\nPlease provide the eligibility or exclusion criteria one by one.","PROBA":0.5163897905},{"ID":"25451_36_NCT03509974","TOPIC_YEAR":2022,"RESPONSE":"\"","PROBA":0.0331099355},{"ID":"6734_15_NCT01662609","TOPIC_YEAR":2021,"RESPONSE":"Our team would be happy to assist you! Please send any supporting documents or information that may be relevant to the patient's eligibility for the clinical trial. Please let us know if you have any questions or concerns.","PROBA":0.6259876078},{"ID":"25109_36_NCT00789061","TOPIC_YEAR":2022,"RESPONSE":"textt>Yes, the patient is eligible for the clinical trial under the inclusion and exclusion criteria provided. Here's how we can determine eligibility based on the provided information:\n\nInclusion Criteria:\n\n* SLC26A4 mutation (this information is not provided in the patient note, but since it is not a mandatory inclusion criterion, it is not a showstopper)\n* Acute fluctuating hearing loss (the patient complains of dizziness and occasional nausea, which may be related to the hearing loss)\n* No history of or current tobacco or alcohol use (the patient does not use tobacco or drink alcohol)\n\nBased on the patient note, the patient meets all three inclusion criteria.\n\nExclusion Criteria:\n\n* There is no information in the patient note that suggests the patient does not fulfill the exclusion criteria.\n\nSince the patient meets all the inclusion criteria and none of the exclusion criteria, the patient is eligible for the clinical trial.\n\nHere is the final summary:\n\nThe patient is eligible for the clinical trial.","PROBA":0.8398102493},{"ID":"6900_15_NCT03022162","TOPIC_YEAR":2021,"RESPONSE":"-Yes \n -No \n -I'm not sure","PROBA":0.6048606316},{"ID":"11521_17_NCT01123928","TOPIC_YEAR":2022,"RESPONSE":"\nPlease provide your answer as a letter (A, B, C, or D) followed by an explanation of the criteria.","PROBA":0.4938541073},{"ID":"33643_71_NCT02142829","TOPIC_YEAR":2021,"RESPONSE":"\nPlease provide your final answer with full justification.","PROBA":0.4633038145},{"ID":"12354_27_NCT00152581","TOPIC_YEAR":2021,"RESPONSE":"\\begin{aligned}  Text & Comment \\\nB:Excluded & The patient is excluded from the clinical trial because they meet one of the exclusion criteria, specifically WCC < 1500\/mm3 or platelet count <90,000\/mm3. \\\n\\end{aligned}  Therefore, the patient is not eligible for the clinical trial.  \n\nPlease note that the patient's history of inguinal hernia surgery is not a factor in determining eligibility for the clinical trial. Additionally, the patient's current treatment with IFN (100 mg\/week) plus RBV (400 mg\/day) and direct antiviral drugs for chronic HCV infection is not relevant to the clinical trial as the trial is focused on assessing the duration of combination treatment with PEGASYS and Ribavirin. ","PROBA":0.8211950262},{"ID":"17430_36_NCT04646252","TOPIC_YEAR":2021,"RESPONSE":"","PROBA":0.0415095575},{"ID":"12707_27_NCT03170076","TOPIC_YEAR":2021,"RESPONSE":"\nPlease be sure to read through the details of the clinical trial to answer this question confidently.","PROBA":0.4624778476},{"ID":"11856_17_NCT03492853","TOPIC_YEAR":2022,"RESPONSE":"}]  Sure, I'd be happy to help! Let me compare the patient note and the inclusion and exclusion criteria for the clinical trial.\n\nInclusion Criteria:\n\n* Age >50 years\n* Known diagnosis of early or advanced AMD\n* Posterior and peripheral fundus features documented with Optos wide-field imaging\n* DNA available for gene polymorphism analysis\n\nThe patient meets all of the inclusion criteria, as they are over the age of 50, have a known diagnosis of AMD, and have undergone imaging with the Optos device. Therefore, the patient is eligible for the clinical trial.\n\nExclusion Criteria:\n\n* Confounding maculopathy of any etiology\n* Myopic refractive error more than -3.0 diopters in either eye\n* Failure to obtain readable color images documenting at least 270 degrees of the retina (three quadrants)\n* Failure to provide a peripheral blood sample for DNA extraction\n\nThe patient does not meet any of the exclusion criteria, as there is no mention of confounding maculopathy, myopic refractive error, or failure to obtain readable color images. Additionally, the patient has provided a peripheral blood sample for DNA extraction.\n\nFinal Summary:\n\nBased on the patient note and the inclusion and exclusion criteria for the clinical trial, the patient is eligible to participate in the study. The patient meets all of the inclusion criteria and does not meet any of the exclusion criteria. Therefore, the patient can be considered eligible for the clinical trial.","PROBA":0.9340557773},{"ID":"20794_30_NCT00221910","TOPIC_YEAR":2022,"RESPONSE":"##### Solution\n\nTo determine the patient's eligibility for the clinical trial, we will compare the patient's information to the inclusion and exclusion criteria of the trial: \n\nInclusion Criteria:  \n\n1. Diagnosis of osteoarthritis.\n\nThe patient has a diagnosis of osteoarthritis, which is an inclusion criterion, so we mark this as \"A: eligible.\"\n\n2. Pain in the calf and knee when bending down.\n\nThe patient experiences pain in the calf and knee when bending down, which is an inclusion criterion, so we mark this as \"A: eligible.\"\n\n3. Limited activity due to pain.\n\nThe patient's pain limits her activity, which is an inclusion criterion, so we mark this as \"A: eligible.\"\n\n4. History of using nonsteroidal anti-inflammatory drugs (NSAIDs) for >2 years.\n\nThe patient has a history of using NSAIDs for more than two years, which is an inclusion criterion, so we mark this as \"A: eligible.\"\n\nExclusion Criteria:  \n\n1. Contraindications to sciatic nerve block (e.g., allergy to local anesthetics, coagulopathy, malignancy or infection in the popliteal area).\n\nThe patient does not have any of the contraindications mentioned in the exclusion criterion, so we mark this as \"B: excluded.\"\n\n2. Significant peripheral neuropathy or neurologic disorder affecting the lower extremity.\n\nThe patient does not have significant peripheral neuropathy or neurologic disorder affecting the lower extremity, so we mark this as \"B: excluded.\"\n\n3. Pregnancy.\n\nThe patient is not pregnant, so we mark this as \"B: excluded.\"\n\n4. Contraindications to, allergies to, and\/or past adverse reactions to local anesthetics.\n\nThe patient does not have any contraindications, allergies to, or past adverse reactions to local anesthetics, so we mark this as \"B: excluded.\"\n\nHistory of alcohol or drug dependency\/abuse.\n\nThe patient does not have a history of alcohol or drug dependency\/abuse, so we mark this as \"B: excluded.\"\n\nAfter analyzing the patient's information against the inclusion and exclusion criteria of the clinical trial, we can conclude that the patient is eligible for participation. Therefore, our final summary is:\n\nPatient Eligibility: A (eligible)\n\nThe patient fulfills all the inclusion criteria and does not meet any of the exclusion criteria, making her eligible for the clinical trial.","PROBA":0.9182844373},{"ID":"16972_36_NCT00991159","TOPIC_YEAR":2021,"RESPONSE":"Our goal is to determine whether the patient is eligible for the clinical trial by comparing the patient's information to the inclusion and exclusion criteria of the clinical trial. To do this, we will first take an in-depth look at the inclusion criteria, and then examine the exclusion criteria. Finally, we will provide a summary indicating whether the patient is eligible or not based on their medical history, age, physical and mental condition, current medications, the clinical trial's inclusion and exclusion criteria, and any other relevant information.\n\nInclusion Criteria:\n\n1. Subjects must be healthy adults with lipid levels that are at or above the upper limit of normal (ULN) to qualify for the trial.\n2. Those who have not taken lipid-lowering medications in the past 12 months prior to dosing.\n\nExclusion Criteria:\n\n* Evidence of clinically significant disease that may increase the risk to the subject of study participation or interfere with interpretation of results.\n* Secondary hyperlipidemia.\n\nBased on the patient's information, she is:\n\nA. Eligible for the clinical trial.\nB. Excluded from the clinical trial.\nC. Not relevant for the clinical trial.\n\nPlease select one of the above options.\n\nPlease select one of the above options.\n\nHere's the summary:\nThe patient is eligible for the clinical trial based on the inclusion criteria. She is within the age range, meets the BMI criteria, and does not take lipid-lowering medications within the past 12 months. However, she needs to be evaluated further regarding her complaints of sleep apnea and PCO, as these might be considered clinically significant diseases that could potentially interfere with the interpretation of results. Moreover, her high BMI and lipidemic status put her at risk for secondary hyperlipidemia, which is an exclusion criterion. Therefore, the patient should be further assessed before confirming her eligibility for the clinical trial.","PROBA":0.7468599929},{"ID":"10377_15_NCT03963453","TOPIC_YEAR":2022,"RESPONSE":"### \n\nBased on the given patient note and the clinical trial inclusion and exclusion criteria, I have analyzed the patient's eligibility for the clinical trial as follows: \n\nInclusion Criteria:\n\n* Age: The patient is 8 years old, which is within the age range of the clinical trial (no specific age range specified). {A: eligible}\n* Diagnosis: The patient has a diagnosis of Duchenne Muscular Dystrophy (DMD), which is the primary condition being studied in the clinical trial. {A: eligible}\n* Physical examination findings: The patient's physical examination findings of weakness and difficulty standing from a sitting position, along with enlarged calf muscles, are consistent with the diagnosis of DMD. {A: eligible}\n\nExclusion Criteria:\n\n* Lack of consent: Not applicable, as the patient is brought to the clinic by their parents, indicating that they have given consent. {B: not relevant for clinical trial}\n* Cognitive disabled: Not applicable, as there is no mention of cognitive disability in the patient's note. {B: not relevant for clinical trial}\n* Language difficulties: Not applicable, as there is no mention of language difficulties in the patient's note. {B: not relevant for clinical trial}\n\nFinal Summary:\nBased on the patient note and the clinical trial inclusion and exclusion criteria, the patient is eligible for the clinical trial.","PROBA":0.8921742481},{"ID":"8630_12_NCT04074902","TOPIC_YEAR":2022,"RESPONSE":"[A: eligible, B: excluded, C: not relevant for clinical trial]\n\nPlease enter your answer here:________________________.\n\nNote: In this clinical trial, patients must be at least 18 years old. The patient in the patient note is 47 years old, which is not within the inclusion criteria. Please indicate if the patient would be eligible or excluded based on this exclusion criterion.","PROBA":0.7080763141},{"ID":"14176_30_NCT03377218","TOPIC_YEAR":2021,"RESPONSE":") \n\nThank you for providing the patient note and clinical trial information. Based on the information provided, I will assess the patient's eligibility for the clinical trial.\n\n1. Inclusion Criteria:\na) Age 18-45 years\nb) Pregnant women\nc) Iodine deficiency\nd) No pre-existing thyroid disease\n\nBased on the patient note, the patient is a 33-year-old woman who is pregnant and has been diagnosed with Hashimoto's thyroiditis, which is a thyroid autoimmune disease. As per inclusion criteria (b) and (d), the patient is eligible for the clinical trial.\n\n2. Exclusion Criteria:\na) Pre-existing thyroid disease\nb) Pregnancy after assisted reproductive technologies\nc) Known hypersensitivity reaction to iodine or selenium, or other components of dietary supplement used in the study\n\nBased on the patient note, the patient does not have any of the exclusion criteria. However, as per inclusion criteria (d), the patient has a history of thyroid autoimmune disease (Hashimoto's thyroiditis), which may not be eligible for the clinical trial.\n\nIn summary, based on the information provided, the patient is NOT eligible for the clinical trial because of the presence of a thyroid autoimmune disease (Hashimoto's thyroiditis), which is one of the exclusion criteria.","PROBA":0.880177524},{"ID":"5252_12_NCT00608140","TOPIC_YEAR":2021,"RESPONSE":"III.\n\nThe patient is eligible for the clinical trial because all inclusion criteria are met, and none of the exclusion criteria are met. \n\nA. Eligible: Marfan's syndrome and known severe mitral valve prolapse with regurgitation (Inclusion Criteria 1 and 3) \n\nB. Eligible: Symptomatic and prepared to undergo mitral valve repair\/replacement surgery (Inclusion Criteria 2) \n\nC. Eligible: echocardiogram shows an EF of 65% (Inclusion Criteria 4) \n\nD. Not relevant for the clinical trial: Past Medical History (excluded by Inclusion Criteria 5 and 6)\n\nExclusion Criteria:\n\nE. Excluded: Significant coronary artery disease\n\nF. Excluded: Heart failure due to active myocarditis, congenital heart disease, or obstructive hypertrophic cardiomyopathy\n\nG. Excluded: Severe tricuspid regurgitation (TR)\n\nH. Excluded: Severe pulmonic regurgitation (PR)\n\nI. Excluded: Moderate to severe stenotic lesions\n\nJ. Excluded: Dependence on chronic inotropic therapy\n\nK. Excluded: Restrictive cardiomyopathy or constrictive pericarditis\n\nL. Excluded: Severe right ventricular dysfunction\n\nM. Excluded: Baseline creatinine greater than or equal to 3 mg\/dL or renal replacement therapy\n\nN. Excluded: Poor transthoracic sonographic windows precluding reasonable assessment of LV endocardial borders from apical imaging\n\nO. Excluded: Inability to perform spirometric exercise testing\n\nP. Excluded: Significant chronic lung disease\n\nQ. Excluded: Any known neoplastic disease other than skin cancer\n\nR. Excluded: Other terminal illness with a life expectancy less than 1 year\n\nS. Excluded: Plan for percutaneous mitral valve procedure\n\nNote: This patient is eligible for the clinical trial because none of the exclusion criteria are present. All inclusion criteria are met, and none of the exclusion criteria are met.","PROBA":0.911242139},{"ID":"12363_27_NCT00216775","TOPIC_YEAR":2021,"RESPONSE":"IIf you are unsure, please give a summary of the patient's situation and ask for clarification.","PROBA":0.4870632555},{"ID":"11891_17_NCT03782051","TOPIC_YEAR":2022,"RESPONSE":"{A: eligible, B: excluded, C: not relevant for clinical trial}","PROBA":0.9086785614},{"ID":"7788_17_NCT00916058","TOPIC_YEAR":2021,"RESPONSE":"Our clinical trial team would be happy to assist you in determining the eligibility of your patient for our clinical trial! Based on the information you provided, we see that our trial is focused on assessing the safety and efficacy of bendamustine in combination with melphalan in patients with multiple myeloma undergoing autologous stem cell transplant. To determine if your patient is eligible, we will need to review their inclusion and exclusion criteria.\n\nIn terms of inclusion criteria, the patient must have multiple myeloma, be undergoing autologous stem cell transplant, and meet certain laboratory and clinical criteria. These criteria include a diagnosis of multiple myeloma confirmed by bone marrow biopsy or immunofixation, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, adequate renal and hepatic function, and certain lab values. Based on the information you provided, it appears that your patient meets these criteria.\n\nIn terms of exclusion criteria, the patient cannot have impaired renal function with a creatinine clearance of less than 25 ml\/min, impaired hepatic function, serious active or uncontrolled infection or medical condition, be pregnant or breastfeeding, or have impaired pulmonary or cardiac function. Based on the information you provided, it appears that your patient does not meet these criteria, as they have systemic amyloidosis (involvement of lungs, tongue, bladder, heart), are on hemodialysis for ESRD, and have a history of melphalan and prednisone, Velcade and thalidomide.\n\nBased on this information, our clinical trial team notes that the patient is [A: eligible and B: excluded] for the clinical trial because they meet all the inclusion criteria and none of the exclusion criteria. Please let us know if you have any further questions or concerns, and we will be happy to assist you and your patient in any way we can.\n\nIn conclusion, the patient is eligible for the clinical trial because they do not meet the exclusion criteria with systemic amyloidosis and previous treatments. To be more specific:\n\n\u2022 Eligible: multiple myeloma, ECOG PS 0-2, undergoing autologous stem cell transplant, adequate renal and hepatic function, \n\u2022 Excluded: No history of impaired renal or hepatic function, active or uncontrolled infection or medical condition, pregnancy, breastfeeding or impaired lung function.","PROBA":0.8024541584},{"ID":"24997_36_NCT00000361","TOPIC_YEAR":2022,"RESPONSE":"}Exclusion criteria not listedHere are the details of the patient's note that impact each of the inclusion\/exclusion criteria:\n\nInclusion Criteria:\n\n* Rapidly progressive sensorineural hearing loss in both ears: The patient experiences dizziness that improves spontaneously with a history of occasional nausea and tinnitus. Past medical history shows sensorineural hearing loss in the left ear. Therefore, the patient meets the inclusion criteria for the study.\n\nExclusion Criteria:\n\n* No history of psychiatric reaction to corticosteroids: The patient has no known history of depression or other psychiatric disorders, making her eligible for the study.\n\nThe patient's note shows no history of heart, lung, digestive, blood, or neurologic disorders, pancreatitis, active peptic ulcer disease, kidney failure, or known autoimmune disease. Also, the patient does not have a history of shingles, HIV, hepatitis C or B, or other autoimmune diseases. Therefore, the patient is eligible for the clinical trial based on the inclusion criteria. However, she is taking levothyroxine, which may be considered a significant medication that could interfere with the study, and this should be discussed with the principal investigator to determine her eligibility. Although the patient is menopausal, it is not specified whether she has used hormone replacement therapy, which could also be relevant to the study. \n\nIn summary, the patient is eligible for the clinical trial based on the inclusion criteria but may need further discussion regarding her medication use and other potential confounding factors before final enrollment.\n\nIn conclusion, the patient is eligible for the clinical trial based on the inclusion criteria but may require additional discussion regarding her medication use and other potential confounding factors before final enrollment, as some exclusion criteria are not explicitly addressed in the patient's note.  ","PROBA":0.7319310012},{"ID":"30880_65_NCT03721991","TOPIC_YEAR":2021,"RESPONSE":"\n\n\n\n\nPlease provide your answer with the labels you promised. \n\n\n\n\n\nI am very excited to work with you. I hope you will have a great day. \n\n\nPlease assist.","PROBA":0.4806505463},{"ID":"7889_17_NCT01713582","TOPIC_YEAR":2021,"RESPONSE":"O: eligible\n\nB: excluded\n\nC: not relevant for clinical trial","PROBA":0.8391210559},{"ID":"18730_27_NCT00910715","TOPIC_YEAR":2022,"RESPONSE":"\nKindly respond using the format provided above. Thank you!","PROBA":0.4367650212},{"ID":"21412_30_NCT04360382","TOPIC_YEAR":2022,"RESPONSE":"  Yes, the patient is eligible for the clinical trial.\n\nHere's why:\n\n Inclusion Criteria:\n1. Patients undergoing cesarean section.\n [A: eligible]\n2. Patients with osteoarthritis. [A: eligible]\n3. Patients who are at least 18 years old. [A: eligible]\n\n Exclusion Criteria: \n1. Emergency cesarean section. [B: excluded]\n\nBased on the patient's information, she is not an emergency cesarean section. Therefore, she meets all the inclusion criteria and none of the exclusion criteria, making her eligible for the clinical trial.","PROBA":0.7954271648},{"ID":"20791_30_NCT00147186","TOPIC_YEAR":2022,"RESPONSE":"'Please provide a clear answer as to whether the patient is eligible or excluded for the clinical trail.'\n\nThe patient is [A:eligible \/ B:excluded \/ C:not relevant for clinical trial] for the clinical trial titled \"The Effectiveness of Hylan GF-20 on Joint Reaction Forces and Kinematic Patterns During Gait in Patients With Knee Osteoarthritis\". The criteria for eligibility and exclusion are as follows:\n\nInclusion Criteria:\n\u2022 The patient is a 47-year-old woman with osteoarthritis of the knee.\n\u2022 She has been using non-steroidal anti-inflammatory drugs (NSAIDs) for the past two years.\n\u2022 She has a small effusion in the right knee and a tender swelling in the popliteal fossa and calf.\n\u2022 The patient does not have a history of trauma to the target knee within the last five years.\n\u2022 She does not have a prior history of viscosupplementation therapy.\n\u2022 She does not have an allergy to avian products.\n\u2022 She does not have an inflammatory disease or joint sepsis.\n\u2022 She does not have a varus\/valgus angle of more than 12 degrees.\n\u2022 She does not have clinically apparent tense effusion.\n\u2022 She is not currently taking oral corticosteroids.\n\u2022 She has not had an intra-articular injection in any joint within the last three months.\n\u2022 She does not have venous or lymphatic stasis in the leg.\n\u2022 She does not have claudication or peripheral vascular disease (PVD).\n\u2022 She does not have a history of major surgery, arthroplasty in the target joint, or arthroplasty in non-target knee within the last six months.\n\u2022 She does not have a current malignancy or a history of malignancy within the last five years, except for non-melanoma skin cancer.\n\u2022 She is not currently planning surgery during the study period.\n\u2022 She does not have diabetes requiring insulin.\n\u2022 She does not have a significant psychiatric or neurological disorder.\n\u2022 She does not have active alcohol abuse or drug abuse within the past year.\n\nExclusion Criteria:\n\u2022 The patient has a history of trauma to the target knee within the last five years.\n\u2022 She has had prior viscosupplementation therapy.\n\u2022 She has an allergy to avian products.\n\u2022 She has an inflammatory disease or joint sepsis.\n\u2022 She has a varus\/valgus angle of more than 12 degrees.\n\u2022 She has clinically apparent tense effusion.\n\u2022 She is currently taking oral corticosteroids.\n\u2022 She has had an intra-articular injection in any joint within the last three months.\n\u2022 She has venous or lymphatic stasis in the leg.\n\u2022 She has claudication or PVD.\n\u2022 She has a history of major surgery, arthroplasty in the target joint, or arthroplasty in non-target knee within the last six months.\n\u2022 She has a current malignancy or a history of malignancy within the last five years, except for non-melanoma skin cancer.\n\u2022 She is currently planning surgery during the study period.\n\u2022 She has diabetes requiring insulin.\n\u2022 She has a significant psychiatric or neurological disorder.\n\u2022 She has active alcohol abuse or drug abuse within the past year.\n\nBased on the information provided, the patient is [B: excluded] from participating in the clinical trial. The patient has a history of prior viscosupplementation therapy, which is one of the exclusion criteria for the study. Additionally, the patient has clinically apparent tense effusion, which is also an exclusion criterion.","PROBA":0.9379001443},{"ID":"25568_36_NCT04331015","TOPIC_YEAR":2022,"RESPONSE":"$ \\label{the:patient} $\n\nThe patient is $ \\color{A} \\text{eligible} $ for the clinical trial because she is older than 18 years old ($ \\color{B} \\text{not eligible} $), and she is a carrier of the c.151C>T, p.Pro51Ser variant ($ \\color{C} \\text{not relevant for clinical trial} $). Additionally, she has auditory data available ($ \\color{A} \\text{eligible} $), and her hearing loss is sensorineural ($ \\color{B} \\text{not eligible} $). Finally, she does not have any medical conditions that would preclude her from participating in the trial ($ \\color{C} \\text{not relevant for clinical trial} $).\n\nConclusion:\nThe patient is $ \\color{A} \\text{eligible} $ for the clinical trial. All inclusion criteria are met. None of the exclusion criteria are met.","PROBA":0.8200127047},{"ID":"33442_71_NCT00580502","TOPIC_YEAR":2021,"RESPONSE":"\nPlease provide the patient's eligibility status using the labels A, B, or C in brackets.\n\nKindly assist me in determining the patient's eligibility for the clinical trial.\n\n\n","PROBA":0.6289187156},{"ID":"8097_17_NCT04309942","TOPIC_YEAR":2021,"RESPONSE":"_______\n\nPlease answer using the 'A: eligible, B: excluded, C: not relevant for clinical trial' labels.","PROBA":0.7488368492},{"ID":"16918_36_NCT00489333","TOPIC_YEAR":2021,"RESPONSE":"##### Please provide your answer with all necessary justifications ########\n\nAs a helpful assistant for clinical trial recruitment, I am happy to assist you in comparing the patient note and the inclusion criteria of the clinical trial to determine the patient's eligibility.\n\nInclusion Criteria:\n\n1. Age: The patient is 32 years old and falls within the age range of 18-65 years old, which is the inclusion criterion for this clinical trial. Therefore, the patient meets this criterion.\n\n2. Body Mass Index (BMI): The patient's BMI is 41.54, which falls within the range of 30-45 kg\/m2, which is the inclusion criterion for this clinical trial. Therefore, the patient meets this criterion.\n\n3. Other medical conditions: The patient does not have any of the medical conditions that are listed as exclusion criteria for this clinical trial (such as diabetes mellitus requiring daily insulin management or active malignancy). Therefore, the patient meets this criterion.\n\nExclusion Criteria:\n\n1. Morbidly obese: The patient's BMI is 41.54, which falls within the range of 30-45 kg\/m2, which is the inclusion criterion for this clinical trial. Therefore, the patient does not meet this exclusion criterion.\n\n2. Taking any cholesterol-lowering medications: The patient is not taking any cholesterol-lowering medications, therefore, the patient meets this criterion.\n\n3. Enrolled in another clinical study in the past 6 months: The patient is not enrolled in any other clinical study, therefore, the patient meets this criterion.\n\nBased on the patient note and the inclusion and exclusion criteria of the clinical trial, the patient is eligible for the clinical trial.\n\nTherefore, I indicate that the patient is eligible for the clinical trial with the label: A: eligible.","PROBA":0.896513111},{"ID":"21458_30_NCT04661111","TOPIC_YEAR":2022,"RESPONSE":"> Patient is eligible for the clinical study based on the information provided in the clinical note and the inclusion and exclusion criteria.\n\nPlease provide an explanation of the eligibility criteria and each criterion to better understand the ruling and aid in identifying potential issues with this patient's eligibility.\n\nHere is the medical summary of the patient's condition:\n\nThe patient is a 47-year-old woman who is complaining of pain in her calf and knee when she bends down. Her medical history is significant for osteoarthritis, for which she has been using nonsteroidal anti-inflammatory drugs NSAIDs for the past two years. Her vital signs are normal, and there is a small effusion in the right knee. The patient does not smoke, but she drinks alcohol occasionally.\n\nBased on the inclusion criteria:\n\n* The patient's age (47 years) is within the inclusion criteria (age = 18 to 70 years).\n* The patient has knee pain, which is an inclusion criterion (knee pain = subjective  severity of knee pain, assessed using visual analog scale (VAS).\n* The patient's medical history of osteoarthritis is an inclusion criterion.\n* The patient's use of nonsteroidal anti-inflammatory drugs (NSAIDs) for the past two years is not excluded in the inclusion criteria.\n\nBased on the exclusion criteria:\n\n* The patient does not have a major injury to the contralateral knee or other weight-bearing joint, which is an exclusion criterion.\n* The patient has not had a surgical procedure of the studied joint within the previous 12 months prior to screening, which is an exclusion criterion.\n* The patient does not have ligament reconstruction in the target knee within 1 year, which is an exclusion criterion.\n* The patient does not have inflammatory arthropathies such as rheumatoid arthritis, lupus, or psoriatic arthritis, which is an exclusion criterion.\n* The patient has not had intra-articular or local peri-articular corticosteroid injections to the study joint\/knee within the previous 3 months prior to screening or to any other joint (beside the study joint) or soft tissue area within the previous month prior to Screening, which is an exclusion criterion.\n* The patient has not had any corticosteroid within the previous month. Steroid inhalants are permitted if the patient has been on a stable regimen for the past month prior to Screening and remains on this regimen throughout the course of the trial, which is an exclusion criterion.\n* The patient has not had intra-articular hyaluronan in the studied joint within the previous 6 months prior to Screening, which is an exclusion criterion.\n* The patient has not had a history of allergic reaction to an intra-articular hyaluronic acid injection, which is an exclusion criterion.\n* The patient is not using glucosamine- or chondroitin sulfate-containing products, which is an exclusion criterion.\n* The patient does not have X-ray findings of acute fractures, severe loss of bone density, avascular necrosis and\/or severe deformity, which is an exclusion criterion.\n* The patient does not have Axial deviation of the lower limbs higher than 20 degrees in valgus or varus on standing X-ray, which is an exclusion criterion.\n* The patient does not have symptomatic osteoarthritis of either hip, contralateral knee or spine that may interfere with functional assessment of the signal knee, which is an exclusion criterion.\n* The patient does not have clinically significant medio-lateral and\/or anterior-posterior instability, which is an exclusion criterion.\n* The patient does not have osteonecrosis of either knee, which is an exclusion criterion.\n* The patient is not receiving or performing physical therapy at Screening, which is an exclusion criterion.\n\nBased on the information provided, the patient is eligible for the clinical trial.\n\nPlease let me know if you have any additional questions or would like further clarification on any of the criteria.","PROBA":0.8920549901},{"ID":"7724_17_NCT00440635","TOPIC_YEAR":2021,"RESPONSE":"_ _ _ _\n\nEligibility:\n* Age >\/=60 years (A)\n* Refractory or relapsed multiple myeloma after at least 2 previous lines of therapy (A)\n* Patients with systemic amyloidosis are eligible if they have no signs of organ failure (A)\n* No prior exposure to bortezomib (B)\nExclusion:\n* Previous exposure to bortezomib in a clinical trial (B)\n* Received nitrosoureas within 6 weeks or any other chemotherapy within 3 weeks before enrollment (B)\n* Received corticosteroids (>10 mg\/day prednisone or equivalent) within 3 weeks before enrollment (B)\n* Peripheral neuropathy of Grade 2 or greater intensity (B)\n* Myocardial infarction within 6 months of enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities (B)\n\nThe patient is NOT eligible for the clinical trial because they have a history of previous exposure to bortezomib and currently receiving corticosteroids. Additionally, the patient has peripheral neuropathy Grade 2 or greater intensity, and has a history of myocardial infarction within 6 months of enrollment.","PROBA":0.884873473},{"ID":"6741_15_NCT01707225","TOPIC_YEAR":2021,"RESPONSE":"(A) Eligible\n(B) Excluded\n(C) Not relevant for clinical trial\n\nPlease provide a final summary at the end to clearly indicate whether the patient is eligible or excluded for the clinical trial.","PROBA":0.9049020544},{"ID":"21339_30_NCT03921801","TOPIC_YEAR":2022,"RESPONSE":"]  Here is my assessment of the patient's eligibility for the clinical trial based on the information provided:\n\nInclusion Criteria:\n\n* Aged 47 or older (confirmed)\n* Complaining of pain in the calf and knee when bending down (confirmed)\n* History of osteoarthritis (confirmed)\n* Currently using nonsteroidal anti-inflammatory drugs (NSAIDs) for the past two years (confirmed)\n\nNot relevant for clinical trial:\n\n* Gender (female)\n* Marital status (living with husband and 3 children)\n* Occasional alcohol consumption\n* Normal vital signs\n* Physical examination findings (effusion in the right knee, tender swelling in the popliteal fossa and calf)\n\nExclusion Criteria:\n\n* Dependent living status (not applicable)\n* Not able to walk without assistive device or 30 minutes without stopping (not applicable)\n* Diagnosed neurological disease or joint disorder and pain during walking (not applicable)\n* Surgery on lower extremities (not applicable)\n* Current musculoskeletal injury (not applicable)\n* Previous cardiovascular event or symptoms during exercise (not applicable)\n* Body mass index <18 or >35 kg\/m2 (not applicable)\n* Contraindications for magnetic resonance imaging (not applicable)\n* Mini Mental State Examination score of 23 points and lower (not applicable)\n\nFinal Summary:\nBased on the information provided, the patient is eligible for the clinical trial based on all inclusion criteria and none of the exclusion criteria.","PROBA":0.9414397255},{"ID":"18960_27_NCT03462329","TOPIC_YEAR":2022,"RESPONSE":">","PROBA":0.1523024982}]
